首页> 外文期刊>Endocrine. >Normal human thyroid cells, BCPAP, and TPC-1 thyroid tumor cell lines display different profile in both basal and TNF-alpha-induced CXCL8 secretion
【24h】

Normal human thyroid cells, BCPAP, and TPC-1 thyroid tumor cell lines display different profile in both basal and TNF-alpha-induced CXCL8 secretion

机译:正常人的甲状腺细胞,BCPAP和TPC-1甲状腺肿瘤细胞系在基础和TNF-α诱导的CXCL8分泌中显示出不同的特征

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

CXCL8 is secreted by both normal human thyrocytes (NHT) and thyroid cancer cell lines. CXCL8 displays several tumor-promoting effects and recent evidences indicate that its concentrations within the tumor microenvironment can impact the clinical course of the malignancy. Aim of this study was to compare the basal secretion of CXCL8 among NHT and thyroid cancer cell lines (TPC-1 and BCPAP), and to assess the specific cell response to TNF-alpha in terms of CXCL8 secretion. NHT primary cultures, TPC-1 and BCPAP cell lines were cultured with or without TNF-alpha (0, 0.1, 1, 10, and 100 ng/ml). CXCL8 levels were measured in the cell supernatants after 24 h. In basal condition, significant differences in the mean levels of CXCL8 were observed among the three cell types: NHT (110.5 +/- 56.2 pg/ml), TPC1 (467.4 +/- 43.2 pg/ml), and BCPAP (1731.8 +/- 493.3 pg/ml), (F = 35.06; p < 0.0001). TNF-alpha significantly and in a dose-response manner induced CXCL8 secretion in NHT (F = 25.53; p < 0.00001), TPC-1 (F = 13.38; p < 0.0001), and BCPAP (F = 9.88; p < 0.001) cells. The magnitude of the TNF-alpha effect (fold-increase vs. basal level of CXCL8) differed significantly among the three cell types (F = 10.47; p < 0.0001). BCPAP were identified as the cells showing the highest basal secretion of CXCL8 and the less responsive to TNF-alpha. NHT, TPC-1, and BCPAP display significant differences in the secretion of both basal and TNF-alpha-induced CXCL8 secretion. These results indicate that the mechanisms regulating the secretion of CXCL8 differ in tumor cells harboring different genetic alterations suggesting that specific strategies aimed at inhibiting CXCL8 secretion will be required.
机译:CXCL8由正常人的甲状腺细胞(NHT)和甲状腺癌细胞系分泌。 CXCL8显示出几种促进肿瘤的作用,最近的证据表明,其在肿瘤微环境中的浓度会影响恶性肿瘤的临床进程。这项研究的目的是比较NHT和甲状腺癌细胞系(TPC-1和BCPAP)中CXCL8的基础分泌,并根据CXCL8分泌评估对TNF-α的特异性细胞应答。在有或没有TNF-alpha(0、0.1、1、10和100 ng / ml)的情况下培养NHT原代培养物,TPC-1和BCPAP细胞系。 24小时后在细胞上清液中测量CXCL8水平。在基础条件下,三种细胞类型之间的CXCL8平均水平存在显着差异:NHT(110.5 +/- 56.2 pg / ml),TPC1(467.4 +/- 43.2 pg / ml)和BCPAP(1731.8 + / -493.3 pg / ml),(F = 35.06; p <0.0001)。 TNF-α显着并以剂量反应方式诱导NHT(F = 25.53; p <0.00001),TPC-1(F = 13.38; p <0.0001)和BCPAP(F = 9.88; p <0.001)中CXCL8分泌细胞。在三种细胞类型之间,TNF-α效应的强度(CXCL8的基础水平的倍增增加)差异显着(F = 10.47; p <0.0001)。 BCPAP被鉴定为显示CXCL8的基础分泌最高且对TNF-α反应较弱的细胞。 NHT,TPC-1和BCPAP在基础分泌和TNF-α诱导的CXCL8分泌方面均显示出显着差异。这些结果表明调节CXCL8分泌的机制在具有不同遗传改变的肿瘤细胞中是不同的,这表明将需要旨在抑制CXCL8分泌的特定策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号